Home

MITCHELL GOLD

CIK 1242882 · Executive Chairman and CEO · last filed 2026-08-06

MITCHELL GOLD is an Executive Chairman and CEO who has filed 75 SEC Form 4 insider transactions across 2 companies since 2017. The most recent filing, for ATTO, was dated Aug 6, 2026. Across all open-market trades the lifetime net is −$9.1M, making them a net seller over the disclosed history. 2 SEC filings were submitted jointly with Attovia Therapeutics, Inc.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

2

Total Filings

75

Lifetime Open-Market Net

-$9.12M

Filer Profile

Reported Address
ALPINE IMMUNE SCIENCES, INC.
188 EAST BLAINE STREET, SUITE 200
SEATTLE, WA 98102
Related Filers
Attovia Therapeutics, Inc. — 2 joint filings, latest 2026-08-06
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ATTO Director — $25.55 — $0 2 2026-08-06
ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted Executive Chairman and CEO 96,000 $64.97 $6.24M -$9.12M 26 2024-05-20

Recent Filings

75 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-06 ATTO Grant (A) — $0 EDGAR
2026-08-06 ATTO Grant (A) — $0 EDGAR
2024-05-20 ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted Mixed −2,736,402 $0 EDGAR
2024-05-10 ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted Exer (M) +13,245 $100.0K EDGAR
2024-01-05 ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted Grant (A) +96,000 $0 EDGAR
2023-12-29 ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted Mixed +26,177 -$19.7K EDGAR
2023-12-27 ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted Mixed — -$1.81M EDGAR
2023-12-21 ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted Mixed — -$47.0K EDGAR
2023-12-19 — Notice (144) −120,000 -$2.40M EDGAR
2023-12-12 ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted Mixed −109,387 -$2.03M EDGAR
Showing 1–10 of 75
Page 1 of 8
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.